Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
The Basics of Cancer Immunotherapy / / Haidong Dong, Svetomir N. Markovic, editors
| The Basics of Cancer Immunotherapy / / Haidong Dong, Svetomir N. Markovic, editors |
| Autore | Dong Haidong |
| Edizione | [Second edition] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 |
| Descrizione fisica | 1 online resource (228 pages) |
| Altri autori (Persone) | MarkovicSvetomir N |
| Soggetto topico |
Immunotherapy
Neoplasms - therapy |
| ISBN |
9783031594755
9783031594748 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Acknowledgements -- Contents -- About the Editors -- Chapter 1: Basic Concepts in Cancer Immunology and Immunotherapy -- Introduction -- Why Do We Have Cancer? -- How Does the Immune System Protect Us from Cancer? -- Why Does the Immune System Fail to Control Cancer Cells? -- Strategies to Harness the Immune System to Fight Cancer Cells -- Advantages and Side Effects of Cancer Immunotherapy -- Future of Cancer Immunotherapy -- Conclusion -- Chapter 2: Immune Checkpoint Inhibitors in Oncology -- Introduction -- Currently Approved Immune Checkpoint Inhibitors -- CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors -- PD-1 (Programmed Death-1) Inhibitors -- PD-L1 (Programmed Death Ligand 1) -- LAG-3 (Lymphocyte Activation Gene-3) Inhibitors -- Novel Immune Checkpoint Inhibitors -- Immune-Related Adverse Events -- Special Circumstances -- Patients with History of Autoimmune Disorders -- Solid-Organ Transplant Recipients -- Conclusion -- Take-Home Messages for Patients -- References -- Chapter 3: Immunotherapies for Cancer: Bi-specific T Cell Engagers (BiTEs) -- Introduction -- T Cell Signaling and BiTEs -- Approved Products and Indications -- Adverse Events and Limitations -- Cytokine Release Syndrome (CRS) -- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) -- Infections -- Future Directions -- References -- Chapter 4: Tumor-Infiltrating Lymphocyte (TIL) Therapy -- References -- Chapter 5: Cellular Therapies for Cancer: Chimeric Antigen Receptor T Cells (CAR-T) -- Introduction -- T Cell Signaling and CAR Constructs -- CAR-T Production: Collection, Composition, Constructs, and Manufacturing -- Collection -- Composition -- Advanced Constructs -- Manufacturing -- Approved Products and Indications -- Lymphoma -- Multiple Myeloma -- Adverse Events and Limitations -- Cytokine Release Syndrome (CRS).
Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) -- Cytopenias and Infections -- Mechanisms of Resistance -- Future Directions -- References -- Chapter 6: Viral Immunotherapy Strategies in Clinical Practice -- References -- Chapter 7: Chemoimmunotherapy Combination for Solid Tumors -- Mechanisms of Chemotherapy and Immunotherapy Combination -- Chemoimmunotherapy in Solid Tumors -- Lung Cancer -- Non-small-Cell Lung Cancer (NSCLC) -- Small-Cell Lung Cancer (SCLC) -- Resectable Lung Cancer -- Breast Cancer -- Melanoma -- Other Cancers -- Genitourinary Cancers -- Head and Neck Cancers -- Gastrointestinal Cancers -- Antibody-Drug Conjugate -- Conclusion and Future Perspectives -- Immunomodulatory Mechanisms -- Strategies for Chemoimmunotherapy Combination -- Potential Biomarkers -- Conclusion -- References -- Chapter 8: Melanoma Immunotherapy -- Part 1: Melanoma and the Immune System -- Inherent Immunogenicity of Melanoma -- Mechanisms of Immune Evasion and Immunosuppression Employed by Melanoma -- Part 2: Current Immunotherapy Treatments for Melanoma -- Part 2a: Unresectable Melanoma -- Interleukin 2 (IL-2) and Tumor-Infiltrating Lymphocyte (TIL) Therapy -- Ipilimumab -- Pembrolizumab and Nivolumab -- Combined Ipilimumab and Nivolumab -- Nivolumab/Retlatinib Combination Therapy -- Comparison of CTLA-4 Monotherapy, PD-1 Monotherapy, and Combination CTLA-4/PD-1 Therapy for Metastatic Melanoma -- Talimogene Laherparepvec (T-VEC) -- Tebentafusp for Uveal Melanoma -- Part 2b: Resectable Melanoma -- Adjuvant Immunotherapy in Resectable Melanoma -- Ipilimumab -- Pembrolizumab and Nivolumab -- Neoadjuvant Immunotherapy in Resectable Melanoma -- Pembrolizumab -- Ipilimumab-Nivolumab -- Nivolumab-Relatlimab -- Unanswered Questions -- Summary -- Part 3: New Treatments on the Horizon -- TIL Therapy -- Vaccines -- TIGIT -- Summary -- References. Chapter 9: Significance of Immune Checkpoints in Lung Cancer -- Introduction -- Staging and Treatments -- Immunotherapy -- Immunotherapy in Perioperative Treatment -- Neoadjuvant Therapy -- Adjuvant Therapy -- Patients with Stage III Disease Receiving Concurrent Chemotherapy and Radiation -- Patients with Advanced or Metastatic Disease -- PD-1 and PD-L1 Inhibitors as Single Agents in Treatment-Naïve Patients -- PD-1 or PD-L1 Inhibitors in Combination with Chemotherapy -- Combination of Anti-PD-1 and Anti-CTLA-4 Agents -- Immunotherapy for Patients with EGFR and ALK Mutations -- Immune Checkpoint Inhibitors in Later Lines of Treatment -- Small-Cell Lung Cancer -- PD-L1 Assessment and Companion Assays -- Conclusion -- References -- Chapter 10: Immunotherapy in Breast Cancer -- Introduction -- Risk Factors -- Basics of Breast Cancer -- Breast Cancer Subtypes -- Early-Stage Breast Cancer: Multidisciplinary Approaches to Treatment -- How Are the Different Treatment Modalities Integrated? -- Breast Cancer and the Immune System -- Chemoimmunotherapy for Early-Stage Triple-Negative Breast Cancer -- Chemoimmunotherapy for Metastatic Triple-Negative Breast Cancer -- Atezolizumab + Chemotherapy in Metastatic TNBC -- Monoclonal Antibodies and Antibody-Drug Conjugates -- Future Directions of Immunotherapy for Breast Cancer -- References -- Chapter 11: Immunotherapy in Genitourinary Malignancies -- Kidney/Renal Cell Carcinomas -- Introduction -- Renal Cell Carcinoma Grade, Stage, and Risk -- Immunotherapy in Renal Cell Carcinoma -- History of Immune Modulation in RCC -- Immunotherapy in Metastatic ccRCC -- Adjuvant Immunotherapy in ccRCC -- Bladder/Urothelial Cancers -- Introduction -- Staging -- Immunotherapy in Bladder Cancer -- Immunotherapy in Non-muscle-Invasive Bladder Cancer (NMIBC) -- Immunotherapy in Localized Muscle-Invasive Bladder Cancer (MIBC). Immunotherapy in Unresectable Bladder Cancer -- Prostate, Testicular, and Penile Cancers -- Immunotherapy in Prostate Cancer -- Immunotherapy in Testicular Cancer -- Immunotherapy in Penile Cancer -- References -- Chapter 12: Immunotherapy for Gastrointestinal Malignancies -- Colorectal, Appendiceal, and Small Bowel Cancer -- Anal Cancer -- Esophageal and Stomach Cancer -- Liver Cancer -- Biliary Tract Cancer -- Pancreatic Cancer -- Neuroendocrine Tumor and Carcinoma -- Summary -- References -- Chapter 13: Immunotherapy in the Solid Organ Transplant Recipient -- Introduction -- Outcomes and Complications of ICI Use in Solid Organ Transplant Recipients -- General ICI Adverse Event Overview -- Outcomes and Adverse Effects by Organ -- Kidney -- Liver -- Heart and Lung -- Summary -- References -- Chapter 14: Diagnosis and Management of Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy -- Introduction -- Grading of Immunotherapy Toxicity -- Dermatologic Toxicity -- Gastrointestinal (GI) Toxicity -- Hepatic Toxicity -- Endocrine Toxicity -- Thyroid Toxicity -- Pituitary-Gonad-Adrenal (PGA) Axis Toxicity -- Diabetes Mellitus, Type 1 -- Pulmonary Toxicity -- Renal Toxicity -- Neurological Toxicity -- Guillain-Barré Syndrome (GBS) -- Myasthenia Gravis (MG) -- Ocular Toxicity -- Rheumatologic Toxicity -- Inflammatory Arthritis and Polymyalgia Rheumatica -- Myalgias and Myositis -- Cardiac Toxicity -- Hematologic Toxicity -- Principles of Corticosteroid Management -- Conclusion -- References -- Chapter 15: Immunotherapy for Head and Neck Cancer -- Introduction -- The Tumor Microenvironment, Tumor Antigens, and Therapeutic Targets for Immunotherapy in HNSCC -- Immunotherapy for Relapsed or Metastatic Disease -- Second-Line Immunotherapy in HNSCC -- First-Line Immunotherapy in HNSCC -- Dual Immunotherapy in HNSCC. Immunotherapy in the Curative Intent Setting -- Markers to Predict Benefit from Immunotherapy -- Future Directions -- References -- Chapter 16: Resources for Patients -- Index. |
| Record Nr. | UNINA-9910872194703321 |
Dong Haidong
|
||
| Cham : , : Springer International Publishing AG, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The Basics of Cancer Immunotherapy / / edited by Haidong Dong, Svetomir N. Markovic
| The Basics of Cancer Immunotherapy / / edited by Haidong Dong, Svetomir N. Markovic |
| Edizione | [1st ed. 2018.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018 |
| Descrizione fisica | 1 online resource (X, 160 p. 8 illus., 4 illus. in color.) |
| Disciplina | 610 |
| Soggetto topico |
Medicine
Health Immunology Cancer research Popular Science in Medicine and Health Cancer Research |
| ISBN | 3-319-70622-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | The Basic Concepts in Cancer Immunology and Immunotherapy -- Therapeutic Targets of FDA-approved Immunotherapies in Oncology -- Melanoma Immunotherapy -- Significance of Immune Checkpoints in Lung Cancer -- Immunotherapy for Genitourinary Cancers -- Next-generation Immunotherapy in Lymphoma Immunotherapy -- Combined Immunothepary with Conventional Cancer Treatment -- Immunotherapy for Other Malignancies -- Management of Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy -- Resources for Patients. |
| Record Nr. | UNINA-9910300265303321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||